Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574717 | 0.78 | SLC6A4 (0.60) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| Vanoxerine SCHEMBL246574 | 0.75 | SLC6A4 (1.00) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| Vanoxerine SCHEMBL15541249 | 0.74 | SLC6A4 (1.00) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| Vanoxerine SCHEMBL725103 | 0.74 | SLC6A4 (1.00) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| SCHEMBL10000765 | 0.74 | SLC6A4 (0.97) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| Vanoxerine SCHEMBL3014060 | 0.73 | SLC6A4 (0.95) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| SCHEMBL8642038 | 0.73 | SLC6A3 (0.49) | SLC6A3SLC6A4SLC6A2MEN1LMNA | |
| SCHEMBL24221220 | 0.73 | SLC6A4 (0.88) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| SCHEMBL726958 | 0.72 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| SCHEMBL1505912 | 0.71 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177874-A1 | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | VEROSCIENCE, LLC | 2018-06-28 | — | — | US | disclosed |
| US-20170209539-A1 | Therapeutic Treatment For Metabolic Syndrome, Type 2 Diabetes, Obesity, Or Prediabetes | VEROSCIENCE LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-9655865-B2 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | VEROSCIENCE, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3090745-A1 | METHODS OF TREATING VASCULAR DISEASES USING BROMOCRIPTINE | VeroScience LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20140051685-A1 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES | VEROSCIENCE, LLC | 2014-02-20 | — | — | US | disclosed |
| US-20130274246-A1 | Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes | VEROSCIENCE, LLC | 2013-10-17 | — | — | US | disclosed |
| EP-2600873-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | ChanRx Corporation (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018795-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | CHANTEST CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20080293735-A1 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | VEROSCIENCE, LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080200453-A1 | Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome | VEROSCIENCE, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-1539153-A4 | THERAPEUTIC TREATMENT FOR THE METABOLIC SYNDROME AND TYPE 2 DIABETES | GEMATRIA SCIENCES LLC (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006012476-A3 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH CORP (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006012476-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1539153-A2 | THERAPEUTIC TREATMENT FOR THE METABOLIC SYNDROME AND TYPE 2 DIABETES | Gematria Sciences, LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050054734-A1 | Therapeutic treatment for the metabolic syndrome, type2 diabetes, obesity, or prediabetes | CINCOTTA ANTHONY H (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050054652-A1 | Methods of treating metabolic syndrome using dopamine receptor agonists | CINCOTTA ANTHONY H (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040220190-A1 | Methods of treating metabolic syndrome using dopamine receptor agonists | CINCOTTA ANTHONY H (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040077679-A1 | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | CINCOTTA ANTHONY H (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004010946-A2 | THERAPEUTIC TREATMENT FOR THE METABOLIC SYNDROME AND TYPE 2 DIABETES | GEMATRIA SCIENCES, LLC (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177874-A1 | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | GPR119, GLP1R, PRLHR | SLC6A3 76/4885SLC6A4 337/4885SLC6A2 168/4885 |
| US-20080200453-A1 | Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome | LIPG, LIPE, GPR119 | SLC6A3 32/4885SLC6A4 168/4885SLC6A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.